Expired activity
Please go to the PowerPak homepage and select a course.

New Horizons in the Management of Small Cell Lung Cancer: Focus on Immune Checkpoint Inhibitors - An Audio-enriched Monograph

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from AstraZeneca.


Tyler Beardslee, PharmD, BCOP
Oncology Pharmacy Specialist: Aerodigestive Oncology
Winship Cancer Institute, Emory University Hospital
Adjunct Clinical Instructor
Mercer University, College of Pharmacy
Atlanta, GA


Dr. Beardslee has disclosed that he has served on the speaker’s bureau for AstraZeneca.

The clinical reviewer, Lisa Holle, PharmD, BCOP, has disclosed that she has served as a consultant to McGraw Hill Education and has received honoraria from HOPA and PharmCon.

The writer, Larry Rosenberg, has disclosed that he has no actual or potential conflict of interest in relation to this program.

Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN-BC, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-20-082-H01-P
Credits: 2.5 hour (0.25 ceu)

Type of Activity: Application
Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 120 minutes


July 31, 2020

Last Reviewed

April 22, 2021 (see updates at the end of the monograph)


July 31, 2021


This accredited activity has been designed for oncology, managed care and specialty pharmacist.

How to Earn Credit

During the period July 31, 2020 to July 31, 2021 participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


To inform and educate oncology, managed care, and specialty pharmacists on the use of emerging immunotherapies for small cell lung cancer (SCLC) including mechanism of action, rationale for use, approved indications, differences between available immune checkpoint inhibitors, common toxicities, management of adverse effects, and patient management strategies, thus leading to improved patient outcomes and quality of life.


Upon completion of this activity, participants should be better able to:

  • Discuss the rationale for using immune checkpoint inhibitors in patients with small cell lung cancer (SCLC)
  • Identify key completed and ongoing clinical trials of immune checkpoint inhibitors for SCLC and approaches for identifying predictive biomarkers
  • Formulate approaches for the prevention and management of toxicities associated with immune checkpoint inhibitor therapy in patients with SCLC


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC or AstraZeneca. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.